SCHEMBL786336

SCHEMBL786336

CC(C)c1cccc(C(C)C)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGK1 P00558 2/20 0.39
PGK2 P07205 2/20 0.39
GABRA1 P14867 2/20 0.38
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
HTR2C P28335 2/20 0.38
HTR2B P41595 2/20 0.38
LMNA P02545 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
FAAH O00519 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
GABRB1 P18505 1/20 0.38
PTGS1 P23219 1/20 0.38
SLC6A2 P23975 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31085146 0.87 UGT2B7 (0.39) PGK1PGK2GABRA1GABRG2GABRB3
SCHEMBL18857235 0.87 PGK1 (0.33) PGK1PGK2GABRA1GABRG2GABRB3
SCHEMBL19889437 0.87 PGK1 (0.33) PGK1PGK2GABRA1GABRG2GABRB3
SCHEMBL9232328 0.87 UGT2B7 (0.39) PGK1PGK2GABRA1GABRG2GABRB3
SCHEMBL21649830 0.87 PGK1 (0.42) PGK1PGK2GABRA1GABRG2GABRB3
SCHEMBL12922238 0.86 CCR1 (0.46) GABRA1GABRG2GABRB3HTR2CHTR2B
SCHEMBL12915226 0.85 CHRNA7 (0.33) PGK1PGK2GABRA1GABRG2GABRB3
SCHEMBL30577788 0.84 IRAK4 (0.41) PGK1PGK2GABRA1GABRG2GABRB3
SCHEMBL906775 0.84 IRAK4 (0.41) PGK1PGK2GABRA1GABRG2GABRB3
SCHEMBL102150 0.84 CCR1 (0.50) LMNACYP1A2CYP3A4HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 759 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720083-A1 FUNCTIONALIZED TETRAHYDROFURAN INTERMEDIATE AND SYNTHESIS THEREOF Quralis Corporation (US) 2026-04-08 EP claimed
WO-2025217072-A1 HIGH DART IMPACT AND TEAR FILMS FROM TITANIUM BASED PREPOLYMER CATALYZED POLYETHYLENES FORMOSA PLASTICS CORPORATION, USA (US) 2025-10-16 WO claimed
WO-2024249886-A1 FUNCTIONALIZED TETRAHYDROFURAN INTERMEDIATE AND SYNTHESIS THEREOF QURALIS CORPORATION (US) 2024-12-05 WO claimed
CN-113912635-A Method for preparing homoallylic silicon derivative by iron catalysis 中国科学院大连化学物理研究所 2022-01-11 CN claimed
CN-113754694-A Method for synthesizing Reidesvir by asymmetric catalysis of non-protecting group nucleoside 上海交通大学 2021-12-07 CN claimed
CN-108383729-A A kind of purposes of organic base as catalyst carbonate synthesis dibasic ester 中国海洋石油集团有限公司 2018-08-10 CN claimed
CN-106543078-A A kind of preparation method of quinoline 中国科学院兰州化学物理研究所苏州研究院 2017-03-29 CN claimed
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 US claimed
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 US claimed
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER-LAMBERT COMPANY LLC 2005-02-24 US claimed
US-4212937-A NITROGEN-CONTAINING HETEROCYCLIC BASE ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1980-07-15 US claimed
WO-2026100259-A1 RADIATION-SENSITIVE COMPOSITION, PATTERN FORMATION METHOD, AND COMPOUND JSR株式会社 2026-05-15 WO disclosed
US-20260098105-A1 PREPOLYMERIZED CATALYST FOR OLEFIN POLYMERIZATION, METHOD OF PRODUCING THIS PREPOLYMERIZED CATALYST AND METHOD OF PRODUCING OLEFIN POLYMER WITH IMPROVED PROCESSABILITY AND OPTICAL PROPERTIES FORMOSA PLASTICS CORPORATION, U.S.A. (US) 2026-04-09 US disclosed
EP-4720083-A1 FUNCTIONALIZED TETRAHYDROFURAN INTERMEDIATE AND SYNTHESIS THEREOF Quralis Corporation (US) 2026-04-08 EP disclosed
WO-2025217072-A1 HIGH DART IMPACT AND TEAR FILMS FROM TITANIUM BASED PREPOLYMER CATALYZED POLYETHYLENES FORMOSA PLASTICS CORPORATION, USA (US) 2025-10-16 WO disclosed
EP-0193280-A2 Catalyst component for olefin polymerization TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) 1986-09-03 EP disclosed
EP-0187034-A2 Process for producing poly-1-butene TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) 1986-07-09 EP disclosed
EP-0157472-A1 Process for polymerization of olefins TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) 1985-10-09 EP disclosed
EP-0156512-A1 Process for preparing catalyst component for polymerization of olefins TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) 1985-10-02 EP disclosed
US-4212937-A NITROGEN-CONTAINING HETEROCYCLIC BASE ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1980-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia DRD1, DRD2, DRD3 PGK1 2015/4885PGK2 2115/4885GABRA1 915/4885
US-20260098105-A1 PREPOLYMERIZED CATALYST FOR OLEFIN POLYMERIZATION, METHOD OF PRODUCING THIS PREPOLYMERIZED CATALYST AND METHOD OF PRODUCING OLEFIN POLYMER WITH IMPROVED PROCESSABILITY AND OPTICAL PROPERTIES DIS3, DRD4, SRP54 PGK1 1897/4885PGK2 3258/4885GABRA1 4571/4885
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 PGK1 2015/4885PGK2 2115/4885GABRA1 915/4885
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 PGK1 2015/4885PGK2 2115/4885GABRA1 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.